Article Information
History
- March 30, 2020.
Article Versions
- Version 1 (February 11, 2020 - 07:36).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Joonatan Palmu, MD1,2,†,
- Jeramie D. Watrous, PhD3,
- Kysha Mercader, BSc3,
- Aki S. Havulinna, DSc2,4,
- Kim A. Lagerborg, BSc3,
- Aaro Salosensaari, MSc5,
- Mike Inouye, PhD6,7,
- Martin G. Larson, SD7,8,
- Jian Rong, PhD7,
- Ramachandran S. Vasan7,9,
- Leo Lahti, PhD5,
- Allen Andres, PhD3,
- Susan Cheng, MD7,10,11,
- Pekka Jousilahti2,
- Veikko Salomaa, MD2,
- Mohit Jain, MD3,* and
- Teemu J. Niiranen, MD1,2,12,*
- 1Department of Internal Medicine, University of Turku, Finland
- 2Department of Public Health Solutions, Finnish Institute for Health and Welfare, Finland
- 3Departments of Medicine and Pharmacology, University of California San Diego, CA
- 4Institute for Molecular Medicine Finland, FIMM-HiLIFE, Finland
- 5Department of Future Technologies, University of Turku, Finland
- 6Department of Public Health and Primary Care, University of Cambridge, United Kingdom
- 7National Heart, Lung and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, MA
- 8Department of Biostatistics, Boston University School of Public Health, Boston, MA
- 9Sections of Preventive medicine and Epidemiology, and Cardiovacsular Medicine, Department of Medicine; Department of Epidemiology; Boston University Schools of Medicine and Public Health, Boston, MA
- 10Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA
- 11Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
- 12Division of Medicine, Turku University Hospital, Finland
- ↵†Corresponding Author: Joonatan Palmu, Department of Internal Medicine, University of Turku, Finland, E-mail: jjmpal{at}utu.fi; Tel: +358 2 313 0000; Fax: +358 2 313 8436
↵* Equal contribution